South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?
How Would Inventory Returns Work In COVID-19 Vaccine Supply Deals? • Source: Shutterstock
In a world struggling for sufficient supplies of COVID-19 vaccines, South Africa refused to use one million doses of AstraZeneca PLC/University of Oxford partner Serum Institute of India Pvt. Ltd.’s vaccine, instead donating the lot to the African Union (AU). Another 500,000 doses are due to arrive in South Africa over the next few weeks and their fate is not yet clear.
The decision followed a study by the Vaccines and Infectious Diseases Analytics Research Unit of the University of the Witwatersrand...
Keep up with the top pharma business news of the week. On the go.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.